Alzheimer's disease is a progressive disorder that causes brain cells to degenerate and die. It is the most common cause of dementia, a continuous decline in thinking, behavioral, and social skills that disrupts a person's ability to function independently. The early signs of the disease include forgetting recent events or conversations. As the disease progresses, a person develops severe memory impairment and loses the ability to carry out everyday tasks. Current Alzheimer's disease medications may temporarily improve symptoms or slow the rate of decline. These treatments can sometimes help people with Alzheimer's to maximize function and maintain independence for a certain time. Different programs and services can help support people with Alzheimer's disease and their caregivers. 

Market scope and structure analysis :

COVID-19 scenario analysis:

Pharmaceutical and biotechnological companies together with governments around the globe are working to combat the COVID-19 outbreak. This is carried out by supporting development of vaccines to schedule for medicines supply chain challenges. Furthermore, there are around 115 vaccine candidates and other 155 molecules that are in the R&D pipeline. Moreover, commonly used drugs such as Hydroxychloroquine have seen huge boost in demand for management of COVID-19. There is an increase in demand for the drug, which has presented huge opportunities for manufacturers of COVID-19 management drugs, as many developed countries are short of the drug. Hence, owing  to the demand for vaccine and treatment drugs for COVID-19, the pharmaceutical and biotechnology industry is anticipated to witness a substantial growth in the next few years.

Top impacting factors: Market Scenario Analysis, Trends, Drivers, and Impact Analysis

Surge in number of incidences of Alzheimer’s disease would help the industry propel during the forecast period. Rise in prevalence of geriatric population is expected to boost the Alzheimer’s therapeutics market in coming years. In addition, se in awareness among population regarding the symptoms caused due to the diseases is projected to propel the Alzheimer’s therapeutics market growth.

Growth in the number of product launches to boost the market

Growth in number of product launches is expected to help the industry flourish during the forecast period. For instance, in February 2020, Biogen prepared to step up manufacturing to support Alzheimer’s launch.

Furthermore, in June 2020, Axsome Therapeutics, Inc., a biopharmaceutical company developing novel therapies for management of central nervous system (CNS) disorders, announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for AXS-05 for the treatment of Alzheimer’s disease (AD). AXS-05 is a novel, oral, investigational NMDA receptor antagonist with multimodal activity. This is the second breakthrough therapy designation granted to Axsome for AXS-05. There is currently no approved treatment for AD agitation.

Surge in number of mergers and acquisitions to propel the market

Increase in number of mergers and acquisitions is anticipated to help the industry grow in the coming years. For instance, in December 2020, Eli Lilly joined ranks of big pharmaceutical companies, by building a position in gene therapy. It paid about $26.50 per share to acquire New York-based Prevail Therapeutics. Furthermore, it acquired Prevail Therapeutics’ two clinical-stage development programs. Prevail Therapeutics has several gene therapies in preclinical testing, which include candidates for a group of neurodegenerative conditions. The conditions include synucleinopathies, as well as Alzheimer's disease and even amyotrophic lateral sclerosis.

Key segments covered:

Key benefits of the report:

• This study presents the analytical depiction of the global Alzheimer’s therapeutics industry along with the current trends and future estimations to determine the imminent investment pockets.
• The report presents information related to key drivers, restraints, and opportunities along with detailed analysis of the global Alzheimer’s therapeutics market share.
• The current market is quantitatively analyzed from 2020 to 2027 to highlight the global Alzheimer’s therapeutics market growth scenario.
• Porter’s five forces analysis illustrates the potency of buyers & suppliers in the Alzheimer’s therapeutics market.
• The report provides a detailed global Alzheimer’s therapeutics market analysis based on competitive intensity and how the competition will take shape in coming years.

Questions answered in the Alzheimer’s therapeutics Market research report:

• Which are the leading market players active in the Alzheimer’s therapeutics market?
• What would be the detailed impact of COVID-19 on the Alzheimer’s therapeutics market??
• What current trends would influence the market in the next few years?
• What are the driving factors, restraints, and opportunities in the Alzheimer’s therapeutics market?
• What are the projections for the future that would help in taking further strategic steps?